TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Alpha Teknova, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.80−0.28 (-3.95%)
Close on Oct 19, 2026
- Market cap
- $364.72M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.67 (+32.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Alpha Teknova, Inc. grew revenue 12.3% to $43.70M over the twelve months to Jun 30, 2026. Free cash flow was -$7.35M.
Revenue
$43.70M
+12.3% vs. a year earlier
Operating income
-$15.81M
TTM Q2 2026
Free cash flow
-$7.35M
TTM Q2 2026
EPS, diluted
-$0.31
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $364.72M
- P/E ratio
- –
- Price to sales
- 8.35
- Price to book
- 5.83
- Dividend yield
- –
- Free cash flow yield
- -2.02%
Fundamentals
- Revenue
- $43.70M
- Net income
- -$16.77M
- EPS, diluted
- -$0.31
- Free cash flow
- -$7.35M
- Book value per share
- $1.17
- Diluted shares
- 54M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$43.70M+12.3% YoY
Gross profit
$15.12M+64.2% YoY
Operating income
-$15.81M
Net income
-$16.77M
EPS, diluted
-$0.31
Free cash flow
-$7.35M
Reported periodTrailing twelve months